Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 33, 2013, Pages 13540-13545

  Pace, Craig S ^a   Song, Ruijiang ^a   Ochsenbauer, Christina ^b   Andrews, Chasity D ^a   Franco, David ^a   Yu, Jian ^a   Oren, Deena A ^a   Seaman, Michael S ^c   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b University of Alabama at Birmingham   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiviral; Neutralization; Synergy

Indexed keywords

BISPECIFIC ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; IBALIZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL EFFECTIVENESS; DRUG POTENCY; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

ANTIVIRAL; NEUTRALIZATION; SYNERGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CHROMATOGRAPHY, GEL; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; INHIBITORY CONCENTRATION 50; NEUTRALIZATION TESTS; SURFACE PLASMON RESONANCE;

EID: 84882404868     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1304985110     Document Type: Article

References (44)

1. Walker LM, et al.; Protocol G Principal Investigators (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470.
2. Wu X, et al.; NISC Comparative Sequencing Program (2011) Focused evolution of HIV-1-neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049):1593-1602.
3. Scheid JF, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333(6049):1633-1637.
4. Wu X, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993):856-861.
5. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-289.
6. Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-640.
7. Pejchal R, et al. (2011) A potent and broad neutralizing Ab recognizes and penetrates the HIV glycan shield. Science 334(6059):1097-1103.
8. McLellan JS, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing Ab PG9. Nature 480(7377):336-343.
9. Diskin R, et al. (2011) Increasing the potency and breadth of an HIV Ab by using structure-based rational design. Science 334(6060):1289-1293.
10. Zhou T, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by Ab VRC01. Science 329(5993):811-817.
11. Burton DR, Weiss RA (2010) AIDS/HIV: A boost for HIV vaccine design. Science 329(5993):770-773.
12. Cohen MS, et al.; HPTN 052 Study Team (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365(6):493-505.
13. Abdool Karim Q, et al.; CAPRISA 004 Trial Group (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996):1168-1174.
14. Celum C, Baeten JM (2012) Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Curr Opin Infect Dis 25(1):51-57.
15. van der Straten A, van Damme L, Haberer JE, Bangsberg DR (2012) How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS 26(7):F13-F19.
16. Grant RM, et al.; iPrEx Study Team (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363(27):2587-2599.
17. Eisingerich AB, et al. (2012) Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS ONE 7(1):e28238.
18. Hessell AJ, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84(3):1302-1313.
19. Hessell AJ, et al. (2009) Effective, low-titer Ab protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15(8):951-954.
20. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6(2):207-210.
21. Mascola JR, et al. (1999) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73(5):4009-4018.
22. Mehandru S, et al. (2007) Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 81(20):11016-11031.
23. Trkola A, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11(6):615-622.
24. Huang J, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human Ab. Nature 491(7424):406-412.
25. Jacobson JM, et al. (2009) Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal Ab, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 53(2):450-457.
26. Kuritzkes DR, et al. (2004) Antiretroviral activity of the anti-CD4 monoclonal Ab TNX-355 in patients infected with HIV type. J Infect Dis 189(2):286-291.
27. Burkly LC, et al. (1992) Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal Ab: Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 149(5):1779-1787.
28. Fessel WJ, et al. (2011) The efficacy of an anti-CD4 monoclonal Ab for HIV-1 treatment. Antiviral Res 92(3):484-487.
29. Freeman MM, et al. (2010) Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral Ab. Structure 18(12):1632-1641.
30. Song R, et al. (2010) Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal Ab with anti-HIV-1 activity in infected patients. J Virol 84(14):6935-6942.
31. Doores KJ, Burton DR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84(20):10510-10521.
32. Bonsignori M, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85(19):9998-10009.
33. Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46(6):1896-1905.
34. Seaman MS, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84(3):1439-1452.
35. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
36. Klein F, et al. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):118-122.
37. Nokta MA, et al. (2001) Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals. AIDS 15(2):161-169.
38. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 96(9): 5215-5220.
39. Edmonds TG, et al. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of Ab inhibition in PBMC. Virology 408(1): 1-13.
40. Jacobson JM, et al. (2010) Phase 2a study of the CCR5 monoclonal Ab PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 54(10):4137-4142.
41. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455(7209):109-113.
42. Wu H, Kwong PD, Hendrickson WA (1997) Dimeric association and segmental variability in the structure of human CD4. Nature 387(6632):527-530.
43. Mao Y, et al. (2012) Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol 19(9):893-899.
44. Bargou R, et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging Ab. Science 321(5891):974-977.